Loading...
•
Dec 31, 2022
Protagonist Q4 2022 Earnings Report
Protagonist Therapeutics reported financial results for Q4 2022 and provided a corporate update.
Key Takeaways
Protagonist Therapeutics announced positive results from the Phase 2 FRONTIER 1 study of JNJ-2113 and the REVIVE study of rusfertide. The company is focused on enrolling patients in the Phase 3 VERIFY study of rusfertide and preparing for pre-commercial launch activities. They are also advancing efforts in the oral hepcidin mimetic program.
Positive results from the Phase 2b FRONTIER 1 study of JNJ-2113 in moderate-to-severe psoriasis pave the way for a Phase 3 pivotal study.
Highly statistically significant results from the randomized withdrawal portion of the REVIVE study of rusfertide in polycythemia vera achieved its primary endpoint.
The company is focused on enrolling patients globally in the Phase 3 VERIFY study of rusfertide in PV.
Protagonist is evaluating pre-clinical compounds and advancing efforts in the oral hepcidin mimetic program.
Protagonist
Protagonist
Forward Guidance
Protagonist Therapeutics provided forward-looking statements regarding the potential benefits of JNJ-2113 and rusfertide, timing of JNJ-2113 clinical trials and potential milestones related to JNJ-2113, and their expected cash runway.
Positive Outlook
- Potential benefits of JNJ-2113
- Potential benefits of rusfertide
- Timing of JNJ-2113 clinical trials
- Potential milestones related to JNJ-2113
- Expected cash runway
Challenges Ahead
- Ability to develop and commercialize product candidates
- Delays or difficulties in enrolling or completing clinical studies
- Potential that results from clinical or non-clinical studies indicate compounds or product candidates are unsafe or ineffective
- Dependence on third parties to conduct clinical studies and manufacture products
- Ability to earn milestone payments under collaboration agreement with Janssen Biotech